DIRS.INFO The most relevant business & tech news

☆ Eli Lilly assures investors it can overcome the high-quality problem of too much demand
▼ + stars: | 2024-04-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly 's raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. At their highs of the morning, shares of Eli Lilly traded above their all-time closing high of $792.28 set on March 4. In general, the more-bullish financial outlook helps make Eli Lilly's high price-to-earnings ratio coming into earnings more tolerable for investors. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Eli Lilly, Eli Lilly's, Lilly, Jim Cramer, Lilly's, Jim, Anat Ashkenazi, Zepbound, It's, Ashkenazi, Dave Ricks, donanemab, Jim Cramer's, Eli Lilly’s, Brendan McDermid Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, U.S, Drug Administration, Nexus Pharmaceuticals, CNBC, FDA Locations: Eisai, Zepbound, Trulicity, Wisconsin, New York City, U.S

☆ Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum
▼ + stars: | 2024-04-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.

Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S

☆ Eli Lilly's top-selling drug last year is softening. But it may not matter for the stock
▼ + stars: | 2024-04-12 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. JPMorgan flagged similar trends for Trulicity, which led all Lilly drugs with $7.13 billion in sales for all of 2023. The thesis is predicated on Eli Lilly growing faster than the broader pharmaceutical industry for years to come. Over the past three years, shares of Eli Lilly have soared nearly 300%, compared with a 24% gain for the S & P 500 . A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

Persons: Eli Lilly, Wells, Lilly, Mounjaro, Jim Cramer, tirzepatide, Zepbound, Eli Lilly's, Novo, Wegovy, drugmaker, Jim Cramer's, Jim, Eli Lilly Pharmaceutical, George Frey Organizations: Wall Street, JPMorgan, Club, Novo Nordisk, Novo, BMO Capital Markets, Drug Administration, FDA, The Club, CNBC Locations: Wells Fargo, Trulicity, Tirzepatide, Danish, Lilly, Provo , Utah

☆ Stocks making the biggest moves premarket: Carvana, Gap, Eli Lilly, UBS and more
▼ + stars: | 2024-03-08 | by ( Hakyung Kim | ) www.cnbc.com time to read: +4 min

The database software maker posted adjusted earnings of 86 cents per share on revenue of $458 million. Analysts had called for earnings of 47 cents per share and $433 million in revenue, according to LSEG. DocuSign reported fourth-quarter adjusted earnings of 76 cents per share on revenue of $712 million for the period. According to analysts surveyed by LSEG, Wall Street had expected earnings of 64 cents per share on $699 million in revenue. Eli Lilly — Shares slipped 1% premarket after the U.S. Food and Drug Administration delayed approving its Alzheimer's drug, donanemab.

Persons: MongoDB, DocuSign, Deutsche, Li, Morgan Stanley, LSEG, Eli Lilly —, —, Sarah Min, Michelle Fox, Jesse Pound Organizations: RBC, Li Auto, Deutsche Bank, Navy, UBS — U.S, UBS, Marvell Technology, Broadcom, Revenue, Textron —, Bank of America, Textron, New York Community Bancorp, Moody's, U.S . Food, Drug Administration, Costco —, LSEG Locations: Swiss, U.S

☆ Eli Lilly says FDA delays approval of Alzheimer's drug in surprise move
▼ + stars: | 2024-03-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly said Friday that the Food and Drug Administration has pushed back its approval decision deadline for the drugmaker's experimental Alzheimer's treatment donanemab in a surprise move. The agency plans to call a last-minute meeting of its outside advisors to further review the treatment's safety and efficacy in a late-stage trial, Eli Lilly said. It's another setback for Eli Lilly, which is racing to compete with Biogen and Eisai. In 2021, the FDA approved an earlier, ill-fated Alzheimer's drug called Aduhelm from Biogen and Eisai, despite a negative recommendation from the agency's advisory panel.

Persons: Eli Lilly, Eli Lilly's, Leqembi, Anne White Organizations: and Drug Administration, FDA Locations: Indianapolis , Indiana, Biogen

☆ Stocks making the biggest moves midday: Nvidia, Marvell Technology, Costco, Eli Lilly and more
▼ + stars: | 2024-03-08 | by ( Samantha Subin | ) www.cnbc.com time to read: +4 min

Marvell Technology — The chip company sank more than 11% on light first-quarter earnings and revenue guidance. Marvell Technology said it anticipated adjusted earnings of 23 cents per share for the first quarter, below the 40 cents expected by analysts polled by LSEG, formerly known as Refinitiv. Samsara posted $276 million in revenue, compared to analysts' expectations for $258 million, per LSEG. DocuSign reported adjusted earnings of 76 cents per share on revenue of $712 million for the period. Analysts polled by LSEG had called for earnings of 64 cents per share on $699 million in revenue.

Persons: Carvana, Eli Lilly —, Goldman Sachs, MongoDB, NYCB, DocuSign, LSEG, Morgan Stanley, Yun Li, Jesse Pound, Pia Singh, Sarah Min, Michelle Fox, Hakyung Kim Organizations: Nvidia —, Nvidia, Marvell Technology, LSEG, RBC Capital Markets, Costco, U.S . Food, Drug Administration, Broadcom, Textron — Textron, Bank of America, Old Navy, New York Community Bancorp, Moody's Investors Service, Amylyx Pharmaceuticals, UBS — U.S, UBS, Auto, Deutsche Bank Locations: U.S, Swiss, China

☆ F.D.A. Delays Action on Closely Watched Alzheimer’s Drug
▼ + stars: | 2024-03-08 | by ( Pam Belluck | ) www.nytimes.com time to read: +1 min

The Food and Drug Administration has decided to delay action on a closely watched Alzheimer’s drug, donanemab, which the agency was widely expected to approve this month. will instead require donanemab to undergo the scrutiny of a panel of independent experts, the drug’s maker, Eli Lilly and Company, said Friday. The decision is likely to surprise many Alzheimer’s experts, doctors and patients who had expected the medication would soon be on the market. The F.D.A.’s move was startling to the company, which had been planning for the agency to greenlight the drug during the first quarter of this year. “We were not expecting this,” Anne White, an executive vice president of Lilly and president of its neuroscience division, said in an interview.

Persons: Eli Lilly, “, Lilly, ” Anne White, ” Organizations: Drug Administration Locations: donanemab

☆ What Eli Lilly investors can learn from the slow launch of a competitor's drug
▼ + stars: | 2024-02-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

Club holding Eli Lilly is expecting to get approval for its Alzheimer's treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. The FDA's decision on Lilly's drug, known as donanemab, is expected by the end of March. In the meantime, Eli Lilly's diabetes and obesity drugs, the heart of our investment thesis, should continue to fuel the lion's share of the company's topline growth. About 2,000 patients are currently taking Leqembi, Biogen said Tuesday, up from 800 at the time of the company's third-quarter report in November. LLY YTD mountain Eli Lilly's stock performance so far in 2024.

Persons: Eli Lilly, drugmaker Biogen, Eli Lilly's, —, Lilly, Biogen, Japan's, Chris Viehbacher, Viehbacher, Morgan Stanley, Lilly's, Donanemab, Mounjaro, Jim Cramer, Leqembi, Jim Cramer's, Jim Organizations: Food and Drug Administration, Drug Administration, Alzheimer's Association, FDA, Club, GE Healthcare, FactSet, Pharmaceutical, CNBC Locations: Indianapolis

☆ In this fast-paced bull market, we're increasing our Club price targets on 4 stocks
▼ + stars: | 2024-02-15 | by ( Zev Fima | ) www.cnbc.com time to read: +8 min

Following last week's $120-per-share price target hike to $750 on strong earnings, we're raising our PT again Thursday to $850. Even at our new $850 price target, Lilly shares still represent a lower PEG than we've seen historically but that provides some margin of safety. Costco price target hike to $770 from $680 Costco also trades at a premium valuation, but we think it's warranted due to the company's reliability and consistency. Salesforce price target hike to $320 from $275 Salesforce is a Club name we recently highlighted in our 10 undervalued stocks commentary . Palo Alto Networks price target change pending Lastly, we are aware that our price target on Palo Alto Networks requires an update as well.

Persons: It's, Eli Lilly, Lilly, Salesforce, –, There's, Jim Cramer's, Jim Cramer, Jim, Robert Nickelsberg Organizations: Wall, PT, Novo Nordisk, Costco, Microsoft, Broadcom, UBS, VMware, JPMorgan, Palo Alto, Palo Alto Networks, Palo, CNBC, Getty Locations: GLP, AVGO, Palo Alto, Palo, New York City

Eli Lilly rode soaring demand for diabetes and weight-loss treatments to a better-than-expected finish in 2023, and the drugmaker expects momentum to carry into the new year. Lilly said on Tuesday that revenue could climb as much as 22% this year, as star sellers like the diabetes drug Mounjaro and its new weight-loss counterpart, Zepbound, gain market share. Mounjaro sales jumped 65% to $2.21 billion in the fourth quarter compared with the third quarter. Doctors also prescribe that drug off-label for weight loss, which is one of the hottest areas of pharmaceutical sales. The share price for Indianapolis-based Eli Lilly and Co. has climbed over 400% since the start of the decade.

Persons: Eli Lilly, Lilly, Doctors, David Ricks, “, ”, FactSet, donanemab Organizations: Company, Revenue, Drug Administration, Indianapolis Locations: Mounjaro, North Carolina

☆ We're raising our price target on Eli Lilly by $120 after its excellent quarter
▼ + stars: | 2024-02-06 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +10 min

Bottom line Eli Lilly delivered a strong report Tuesday. Still, it's not a surprise to see shares of Eli Lilly fall nearly 2% Tuesday, to around $694 each. Despite doubling manufacturing capacity year over year in 2023, Eli Lilly said demand for its GLP-1s is "likely to outpace supply" this year. We're raising our Eli Lilly price target to $750 a share from $630, while reiterating our 2 rating on the stock, meaning we'd wait for a pullback before adding to our position. Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.

Persons: Eli Lilly's, Lilly's, Eli Lilly, Mounjaro, Zepbound, it's, —, Jim Cramer, Anat Ashkenazi, NASH, Lilly, Jim, Jardiance, Verzenio, Trulicity, donanemab, Ashkenazi, Jim Cramer's, George Frey Organizations: Revenue, LSEG, U.S, Novo Nordisk, Food and Drug Administration, Analysts, Investors, FDA, CNBC, Bloomberg, Getty Locations: Mounjaro's, U.S, Mounjaro, Trulicity, Provo , Utah

☆ Eli Lilly results blow past estimates on strong Zepbound launch, surging Mounjaro revenue
▼ + stars: | 2024-02-06 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Eli Lilly on Tuesday reported fourth-quarter revenue and adjusted earnings that topped expectations on the strong launch of its new weight loss drug, Zepbound, and higher prices for its blockbuster diabetes drug, Mounjaro. Zepbound, which won approval from U.S. regulators in early November, raked in $175.8 million in sales for the fourth quarter. Shares of Eli Lilly were up 5% in premarket trading Tuesday. With a market cap of roughly $673 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.Eli Lilly will hold an earnings call with investors at 10:00 a.m.

Persons: Eli Lilly, Eli Lilly's, Mounjaro Organizations: LSEG, FactSet Locations: San Diego , California, U.S

☆ Exclusive-Eisai Expects 1,500 Alzheimer's Patients in China Launch, Sees ‘Huge’ Growth
▼ + stars: | 2024-02-04 | by ( Feb. | At P.M. | ) www.usnews.com time to read: +5 min

“China is one of the fastest-aging countries in the world and is one of the most important countries in the area of Alzheimer’s disease for Eisai,” a company spokesperson said. “The potential growth for Leqembi in China is huge.”Eli Lilly, which is developing a similar treatment called donanemab, told Reuters it has filed for approval in China. The Indianapolis-based company is now testing its drug in a 1,500-person trial with volunteers in China, Taiwan, South Korea and the EU, a spokesperson said. Leqembi, which works by removing a toxic protein called beta amyloid from the brain, is the first Alzheimer's treatment proven to alter the course of the fatal, brain-wasting disease. Once on treatment, suitable patients undergo a series of MRI scans to monitor for potentially fatal swelling and bleeding in the brain.

Persons: Julie Steenhuysen, Andrew Silver CHICAGO, ” Eli Lilly, Biogen, Liu Zhou, Eisai, ”, Hidemaru Yamaguchi, Soeren Mattke, Mattke, Andrew Silver, Caroline Humer, Bill Berkrot Organizations: Reuters, EU, Leqembi, Guangdong Medical University, ” Citi, Psychiatry, Siemens Healthineers, University of Southern, University of Southern California Brain Health Locations: SHANGHAI, China, ”, Leqembi, The Indianapolis, Taiwan, South Korea, Eisai, United States, Japan, Europe, U.S, University of Southern California, Chicago, Shanghai

☆ Eli Lilly's Zepbound is off to a strong start, but here's what needs to happen to push shares higher
▼ + stars: | 2024-01-24 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Lilly's Mounjaro and Zepbound both use tirzepatide as an active ingredient, but Mounjaro is indicated for type 2 diabetes, while Zepbound aids weight loss. A rich valuation LLY 1Y mountain Eli Lilly shares over the past year. But even good news about Zepbound's launch might not be enough to propel Lilly's stock higher. Goldman's Shibutani has a neutral rating on Lilly shares and a price targe of $600, which implies shares could fall nearly 5% from they started the week. He has a buy rating on Lilly shares, and expects the stock could hit $700 over the next 12 months.

Persons: Eli Lilly's, Lilly, Goldman Sachs, Chris Shibutani, IQVIA, Shibutani, Lilly's, Mounjaro, Eli Lilly, Geoff Meacham, NASH, Meacham, there's, Morgan Stanley, Terence Flynn, Flynn, Morgan Stanley's, Michael Bloom Organizations: Food and Drug Administration, Zepbound, Novo Nordisk's, Medicare, Bank of America, Novo Nordisk, Bank of, FDA, CNBC Locations: Indianapolis, Mounjaro

☆ Why we like health-care stocks in 2024 despite their spotty record in presidential election years
▼ + stars: | 2024-01-18 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +11 min

The S & P 500 Health Care Sector index has outperformed the broader S & P 500 in just three of the past eight presidential election years dating back to 1992, according to FactSet data. So far in 2024, health care has been the best-performing sector in the S & P 500, climbing roughly 2%. .GSPHC .SPX YTD mountain Health care sector vs. S & P 500 YTD It's way too early for any grand predictions with Election Day 2024 about 10 months away. Nevertheless, we see attractive fundamentals in the year ahead for a host of health-care stocks, giving us the confidence to own Lilly, GE Healthcare and Danaher despite what history says about the group in presidential election years. After a strong 2022 for health care in a terrible overall market, investors last year placed a lower emphasis on the defensive characteristics of health care.

Persons: —, that's, Eli Lilly, Lilly, Jim Cramer, Jim, Sen, Bernie Sanders of, Joe Biden, Sanders, would've, Damien Conover, Conover, Biden, Eli Lilly's, Morningstar, Amgen, Morningstar's Conover, Lilly's donanemab, Humana, Bausch, Jim Cramer's, Frederick Florin Organizations: Health, GE Healthcare, Abbott Laboratories, Amgen, Novartis, Walgreens Boots Alliance, JPMorgan Healthcare Conference, Democratic, Morningstar, CNBC, Horizon Therapeutics, Novo Nordisk, Federal Reserve, General Electric, Medicare, Humana, UnitedHealth Group, Investors, AFP, Getty Locations: San Francisco, U.S, Bernie Sanders of Vermont, Canadian, Fegersheim, France

☆ 4 stock ideas I brought back from the JPMorgan Healthcare Conference and everything else I learned about the industry
▼ + stars: | 2024-01-15 | by ( Jim Cramer | ) www.cnbc.com time to read: +12 min

We will go over them – but first, let me talk about what I learned at last week's JPMorgan Health Care Conference that I attended in San Francisco, and what it means to your portfolio. We know health care has a lot of angles too it. The previous CEO Roz Brewer was from Starbucks and struggled with the role that Walgreens plays in health care. You have to be following the transformation of Bristol-Myers, which is opening its wallet to buy a host of drug companies, including anti-psychotic firm Karuna. Health care is the way to go.

Persons: Regeneron, Pfizer, Eli Lilly, Dave Ricks, Lilly, donanemab, Lilly's, Zepbound, it's, Abbott, It's, Roche, Merck, Myers, ABT, Robert Ford, Tim Wentworth, He's, Roz Brewer, Wentworth, he'll, Brewer wasn't, Bob Bradway, Amgen, Vas Narasimhan, Sandoz, Karuna, Medtronic, Hugo, Morgan Stanley, Wells, Covid, Cramer's, Jim Cramer, Jim, Las Vegas Brendan Smialowski Organizations: Abbott Labs, Covid, Novartis, Amgen, Walgreens Boots Alliance, JPMorgan Health Care Conference, Humana, Drug Administration, Novo Nordisk, Dickinson Co, Bristol, Myers Squibb, Pfizer, Department, WBA, Walgreens, Starbucks, -, pharma, Merck, Keytruda, Horizon Therapeutics, Federal Trade Commission, Myers, BD, CVS Health, JPMorgan, Cramer's Charitable, CNBC, Consumer, AFP, Getty Locations: San Francisco, GLP, North Carolina, Europe, Cencora, Amgen, West, Bristol, Target, Las Vegas

☆ Here’s a rapid-fire update on all 33 stocks in our portfolio, including those Cramer would buy on dips
▼ + stars: | 2023-12-19 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +14 min

Here's a rapid-fire update on all the stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. If we get a sell-off in January, Eaton is a logical place to look to buy, Jim said. Procter & Gamble : It's possible that 2024 is a better year for P & G the company than P & G the stock, Jim said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, they'll, we've, there's, he'd, Dupont De, Ed Breen, Danaher, Walt Disney, Bob Iger, Trian's Nelson Peltz, Estee Lauder, Bausch, we're, Eaton, Mary, Eli Lilly's, he's, Vimal Kapur, Kapur, We've, Eli Lilly, Mark Zuckerberg, Morgan Stanley, Morgan, Elliott, Stanley Black, Decker, TJ Maxx, Charlie Scharf, it's, Jim Cramer, Virginia Sherwood Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Broadcom, VMWare, Bausch, Bausch Health, Charitable Trust, Caterpillar, Federal, Costco Wholesale, Coterra Energy, Dupont De Nemours, Fed, Walt, Eaton Corporation, Ford, GE Healthcare, Google, Honeywell, New, Facebook, Meta, Reality Labs, Microsoft, Activision Blizzard, Nvidia, AMD, Apple, Palo Alto Networks, Procter & Gamble, Constellation Brands, Elliott Management, Constellation, Modelo, Corona, Street, TJX, TJ, Wynn Resorts, Jim Cramer's Charitable, NYSE Locations: hospitalizations, China, U.S, Palestine, Wells Fargo

☆ Why Pfizer's latest stumble in the obesity market is a boon for Eli Lilly
▼ + stars: | 2023-12-01 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +5 min

In June, the New York-based pharmaceutical giant stopped developing a different obesity pill, known as lotiglipron , due to concerns about liver safety. Meanwhile, Eli Lilly shares were mainly flat in afternoon trading, at around $591apiece. We lifted our Eli Lilly price target Friday to $630 per share, up from $600. Eli Lilly and Danish rival Novo Nordisk (NVO) are the two dominant players in the obesity market. The longer it takes for competitors to get to this burgeoning market, the more revenue first-movers Eli Lilly and Novo Nordisk can capture.

Persons: Eli Lilly, Jim Cramer, Lilly's, Novo's, Jim, Eli Lilly —, —, Eli, that's, — Novo's, Novo, semaglutide, Jim Cramer's, AJ Mast Organizations: Pfizer, Club, Novo Nordisk, Pharmaceutical, Amgen, AstraZeneca, Bank of America, U.S . National Library of Medicine, U.S . Food, Drug Administration, CNBC, Bloomberg, Getty Locations: New York, Danish, Lilly, U.S, Indianapolis , Indiana

☆ We're updating price targets for 6 stocks and changing our rating for Palo Alto
▼ + stars: | 2023-12-01 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

The Club on Friday is changing the rating and price target on one of our favorite stocks, and updating the price targets on 5 other names in the portfolio to reflect recent quarterly earnings reports, new developments at the companies and broader economic forces. We're increasing our price target on shares of Palo Alto (PANW) to $300 from $280. We're raising our price target on shares of Salesforce (CRM) to $275 from $240. We're lowering our price target for Ford (F) stock to $13 from $16. We're lifting our price target on shares of Eli Lilly (LLY) to $630 from $600.

Persons: PANW, Ford, Linde's, Linde, Eli Lilly, it's, It's, Jim Cramer's, Jim Cramer, Jim Organizations: Palo, Palo Alto Networks, Costco, Ford, UAW, Management, Motors, GM, Linde, LIN, P Healthcare, donanemab, Novo Nordisk, Pfizer, CNBC Locations: Alzheimer's, Lilly, Santa Clara , California

☆ Researchers return to Alzheimer's vaccines, buoyed by recent drug success
▼ + stars: | 2023-11-20 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +6 min

The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis. Dr. Reisa Sperling, an Alzheimer's researcher at Mass General Brigham in Boston, said she believes vaccines will play an important role as researchers look to prevent Alzheimer's. She is considering vaccines for her next study in asymptomatic people with Alzheimer's proteins in their blood, but not enough to register on brain scans. Alzheimer's vaccines are still in the early stages and will require large, years-long trials to show they work. Generating a strong immune response is critical for such vaccines, which would typically be given to older individuals with weaker immune systems, he said.

Persons: Brian Snyder, Eli Lilly's, Reisa Sperling, Brigham, “, ” Sperling, Walter Koroshetz, Mei Mei Hu, Vaxxinity, Hu, Michael Rafii, Rafii, Andrea Pfiefer, Johnson, Prothena, Gene Kinney, Julie Steenhuysen, Caroline Humer, Bill Berkrot Organizations: Alzheimer Research, Brigham, Women's, REUTERS, Rights, U.S . Food, Drug Administration, Mass, National Institutes of Health, UB, University of Southern, Johnson, Bristol Myers Squibb, Thomson Locations: Boston , Massachusetts, U.S, Boston, Taiwan, University of Southern California

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. The company declined to comment on the plans but news conferences are planned in Alzey, where sources say the plant will be built, and Berlin on Friday. Other people familiar with the plans told Reuters that at least 1,000 jobs would be created. Eli Lilly said it would unveil "far-reaching investment plans" at Friday's news conference, which will be attended by Germany's economy and health ministers. Mounjaro's success helped Lilly post a 37% gain in third-quarter revenues to $9.5 billion, topping Wall Street estimates.

Persons: Eli Lilly, Mike Segar, Mounjaro, TSMC, Lilly's, Lilly, Rene Wagner, Klaus Lauer, Andreas Rinke, Ludwig Burger, Thomas Escritt, Madeline Chambers, Miranda Murray, Christina Fincher Organizations: Company, REUTERS, Basf, Reuters, BASF, U.S ., U.S, Intel, European Union, Novo Nordisk, U.S . Food, Drug Administration, Thomson Locations: Branchburg , New Jersey, BERLIN, Germany, Alzey, Berlin, U.S, Ukraine, European, Indianapolis, Danish, Eisai

☆ Monthly Meeting Q&A with Jim Cramer on 20 stocks in everything from tech to industrials to drugs
▼ + stars: | 2023-11-16 | by ( Paulina Likos | ) www.cnbc.com time to read: +12 min

(Anthony) Jim Cramer: There were some China statistics that showed that the consumer was doing slightly better. (David) Jim Cramer: The roadblock is that the money is at the state level. (Narayan) Jim Cramer: " Own, don't trade" is about trying to keep us in a stock that otherwise we would trade out of. (Jim) Jim Cramer: First, I think we have to remember Ford actually has a lot of money on its balance sheet — a lot of cash. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

Persons: Jim Cramer's, Jeff Marks, Estee Lauder, Anthony, Jim Cramer, Wynn, It's, David, I'm, Narayan, it's, Steve Jobs, John, Tom Jorden, That's, Capex, Paul, Procter, Jim Farley, Jim, Ford, Shawn Fain, Farley, Donald, Larry Culp, He's, GEHC, Eli Lily, Louis, Lilly, Zepbound, We've, Alzheimer's, tirzepatide, hasn't, Edmundo, we've, haven't, Linde, Theresa, Jim Cramer Rob Kim Organizations: Investing Club, Club, Caterpillar, Amazon, Nvidia, Apple, Web Services, Natural Resources, Exxon, Procter, Gamble, United Auto Workers, GE Healthcare, Electric, GE, General, Merck, Drug Administration, Novo Nordisk, Linde, LIN, Trust, Barrick, CNBC Locations: China, reaccelerate, GEHC

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsBERLIN, Nov 15 (Reuters) - U.S. pharma company Eli Lilly (LLY.N) plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a news conference for Friday. Eli Lilly said it would unveil "far-reaching investment plans" at Friday's news conference, which will be attended by Germany's economy and health ministers. Mounjaro's success helped Lilly post a 37% gain in third-quarter revenues to $9.5 billion, topping Wall Street estimates. The group's market value has ballooned to around $580 billion, up more than 65% so far this year.

Persons: Eli Lilly, Mike Segar, Mounjaro, TSMC, Lilly's, Lilly, Rene Wagner, Klaus Lauer, Ludwig Burger, Thomas Escritt, Chizu Nomiyama, Jane Merriman Organizations: Company, REUTERS, Rights, . pharma, Reuters, U.S ., U.S, Intel, European Union, Novo Nordisk, U.S . Food, Drug Administration, Thomson Locations: Branchburg , New Jersey, Germany, Rhineland, Palatinate, U.S, Ukraine, European, Indianapolis, Danish, Eisai

☆ Here’s a rapid-fire update on all 35 stocks in our portfolio, including a new industrial
▼ + stars: | 2023-11-15 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +14 min

Here's a rapid-fire update on all the stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Honeywell International (HON): This is the most undervalued stock in our portfolio, Jim said. In a diversified stock portfolio, Jim said there's always room for high-quality companies like P & G, which also has a track record of raising its dividend. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. Here's a rapid-fire update on all the stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club.

Persons: Jim Cramer's, Jim, Bausch, That's, Dupont De Nemours, Dupont, Danaher, Walt Disney, Estee Lauder, Locker, Vimal Kapur, we're, We've, we've, Linde, Eli Lilly, Eli, hasn't, Mark Zuckerberg, Meta's, Zuckerberg, Morgan Stanley, Morgan Stanley's, Ted Pick, James Gorman, he's, there's, Patience, Stanley Black, Decker, Wells Fargo, Jim Cramer Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Amazon Web Services, Broadcom, VMWare, Bausch Health, Caterpillar, Costco Wholesale, Coterra Energy, Disney, Eaton Corp, Emerson, Ford, Union Auto Workers, GE Healthcare Technologies, General Electric, GE, Management, Google, YouTube, Honeywell International, Honeywell, Linde, LIN, Reality Labs, Microsoft, Nvidia, U.S, Oracle, Palo Alto Networks, Procter & Gamble, Starbucks, Constellation Brands, Corona, Modelo, Stanley, TJX, Wynn Resorts, WYNN, Trust Locations: China, India, Salesforce's, redeploy

☆ AstraZeneca adds player to obesity drug race, but Eli Lilly remains in the lead
▼ + stars: | 2023-11-10 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

Eli Lilly (LLY) remains our favorite way to play the weight-loss drug market, despite a new entry this week from AstraZeneca (AZN). Eli Lilly shares had their worst day of the year Thursday, falling 4.5% in the session to close at $591.32. AstraZeneca's encroachment on turf currently dominated by Eli Lilly and Danish rival Novo Nordisk (NVO) may have contributed to Thursday's declines. That approval, despite being widely expected, pushed Eli Lilly to an all-time closing high Wednesday, at $619.13 per share. Our desire to own Eli Lilly over Novo Nordisk hinges, in part, on our confidence in Eli Lilly's other treatment opportunities, such as in Alzheimer's.

Persons: Eli Lilly, Jim Cramer, Jim, Lilly's, Eli Lilly's tirzepatide, Zepbound, Novo's, Eli Lilly's, Eli Lilly's GLP, Dave Ricks, Lilly, Ricks, AstraZeneca's, ECC5004, retatrutide, Jim Cramer's, David Ricks, Eli Lilly Scott Mlyn Organizations: AstraZeneca, Novo Nordisk, American Heart Association, Novo Nordisk's semaglutide, CNBC, Reuters, Citigroup Locations: Danish, GLP, North Carolina, Novo, Denmark, Zepbound, Alzheimer's

Search resuls for: "Donanemab"

25 mentions found